Author:
Somogyi Eszter,Kremlitzka Mariann,Csiszovszki Zsolt,Molnár Levente,Lőrincz Orsolya,Tóth József,de Waal Leon,Pattijn Sofie,Reineking Wencke,Beineke Andreas,Tőke Enikő R.
Abstract
BackgroundThe emergence of novel SARS-CoV-2 variants that resist neutralizing antibodies drew the attention to cellular immunity and calls for the development of alternative vaccination strategies to combat the pandemic. Here, we have assessed the kinetics of T cell responses and protective efficacy against severe COVID-19 in pre- and post-exposure settings, elicited by PolyPEPI-SCoV-2, a peptide based T cell vaccine.Methods75 Syrian hamsters were immunized subcutaneously with PolyPEPI-SCoV-2 on D0 and D14. On D42, hamsters were intranasally challenged with 102 TCID50 of the virus. To analyze immunogenicity by IFN-γ ELISPOT and antibody secretion, lymphoid tissues were collected both before (D0, D14, D28, D42) and after challenge (D44, D46, D49). To measure vaccine efficacy, lung tissue, throat swabs and nasal turbinate samples were assessed for viral load and histopathological changes. Further, body weight was monitored on D0, D28, D42 and every day after challenge.ResultsThe vaccine induced robust activation of T cells against all SARS-CoV-2 structural proteins that were rapidly boosted after virus challenge compared to control animals (~4-fold, p<0.05). A single dose of PolyPEPI-SCoV-2 administered one day after challenge also resulted in elevated T cell response (p<0.01). The vaccination did not induce virus-specific antibodies and viral load reduction. Still, peptide vaccination significantly reduced body weight loss (p<0.001), relative lung weight (p<0.05) and lung lesions (p<0.05), in both settings.ConclusionOur study provides first proof of concept data on the contribution of T cell immunity on disease course and provide rationale for the use of T cell-based peptide vaccines against both novel SARS-CoV-2 variants and supports post-exposure prophylaxis as alternative vaccination strategy against COVID-19.
Subject
Immunology,Immunology and Allergy
Reference49 articles.
1. Who Coronavirus (Covid-19) Dashboard,2022
2. Efficacy of a fourth dose of covid-19 mrna vaccine against omicron;Regev-Yochay;N Engl J Med,2022
3. Adapted Vaccine Targeting Ba.4 and Ba.5 Omicron Variants Original Sars-Cov-2 Recommended for Approval,2022
4. Current evidence for covid-19 therapies: A systematic literature review;Welte;Eur Respir Rev,2021
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献